Patient Support Services Contact Us

Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News
04/19/19
REDWOOD CITY, Calif. , April 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective April 18, 2019 , the compensation committee of the company’s board of directors granted six new employees, a Senior Vice President, and another Senior Vice President,
04/05/19
REDWOOD CITY, Calif. , April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that UDENYCA™ preliminary unaudited net sales for the quarter that ended March 31, 2019 are expected to be in the range of $36.0 million to $38.0 million .
04/05/19
REDWOOD CITY, Calif. , April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2019 financial results will be released after market close on Thursday, May 9, 2019 . Starting at 4:30 p.m.
03/28/19
REDWOOD CITY, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 12:10 p.m. GMT .

Receive E-mail Alerts

Click here to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site.

 

Copyright West LLC. Minimum 15 minutes delayed.